Author: Newsdesk

Posted on

Israel Corp. Reports Results for Third Quarter of 2020

PR Newswire

TEL AVIV, Israel, Nov. 19, 2020 /PRNewswire/ — Israel Corporation Ltd. (TASE: ILCO) (“IC”) announced today its third quarter results for the period ending September 30, 2020.

 



Selected Financial Figures for the Third Quarter 2020:


$m


Q3/20


Q3/19


IC share in ICL profit


24


60


IC share in Bazan profit (loss)


(17)


3

Amortization of excess cost

(2)

(3)

Financing, G&A and other expenses at IC headquarter level

(21)

(18)

Tax income (expenses) of IC headquarters

–

–


Net Profit (Loss) to company’s shareholders


(16)


42

 


Debt Balances and Liquidity at the IC Headquarters Level1

As of September 30, 2020, total financial liabilities1 were $1,649 million, and investments in liquid assets amounted to $624 million of which $84m are pledged deposits.

Net debt1 as of September 30, 2020 totaled $1,018 million. The net debt includes the fair value of derivatives transactions, which decrease the economic value of the financial liabilities in the amount of $7 million. As of June 30, 2020, the net debt1 was $1,013m.


Additional updates

Following the outbreak of the Corona Virus (COVID-19) in China in December 2019, and its spread to many other countries in 2020, there has been a decline in economic activity in many regions of the world and in Israel as well.

As a holding company, the financial results of IC are mainly affected by the results of its held companies and the market value of its traded held companies. For more details see detailed financial report.

 



IC Total Assets, Net


$m


30/09/2020


Assets

ICL (~587m shares, market value2)

2,068

Bazan (~1,058m shares , market value2)

188


Total Assets


2,256

IC’s Net Debt

1,018


Total Assets, net


1,238

 


About Israel Corporation

Israel Corporation Ltd. (TASE: ILCO) (“IC”) is a reputable public investment company, which owns and invests in high quality companies with established managements and go-to markets.

In November 2019, IC announced its updated strategy, IC plans to expand its portfolio through new investments in total amount of $350m–500m over the next few years. IC plans to focus mainly in the food (inc. tech), agriculture (inc. tech), healthcare and industry 4.0 sectors. For more details please see the following link to IC updated Strategy Presentation

IC strives to generate return on our investment through active board participations and our operational and managerial expertise.

IC current core holdings include c.46% stake in ICL Group (NYSE:ICL, TASE:ICL) and a c.33% stake in the Bazan Group (TASE:ORL). IC is publicly traded on the Tel Aviv Stock Exchange under the ticker ILCO.

For further information on IC, see IC’s publicly available filings, which can be found on the Tel Aviv Stock Exchange website at http://maya.tase.co.il.

Please also see IC company website http://www.israelcorp.com for additional information.

Convenience Translation

The financial information found in this press release is an English summary based on the original Hebrew financial statements and is solely for the convenience of the reader. The binding version is the original in Hebrew.

Forward Looking Statements

This press release may contain forward-looking statements, which may not materialize and are subject to risks and uncertainties that are not under the control of IC, which may cause actual results to differ materially from those contained in the disclosures.

1Israel Corp and its wholly owned and controlled headquarter companies.
2As of September 30, 2020.


Investor Relations Contacts


Idan Hizki
Senior Director, Business Development & Investor Relations
Tel: +972 3 684 4500
[email protected]

 

 

Cision View original content:http://www.prnewswire.com/news-releases/israel-corp-reports-results-for-third-quarter-of-2020-301177487.html

SOURCE Israel Corporation Ltd.

Posted on

Physician and nurse perceptions of teamwork and collaboration differ on general medical services

Study in December 2020 issue of The Joint Commission Journal on Quality and Patient Safety

OAKBROOK TERRACE, Ill., Nov. 19, 2020 (GLOBE NEWSWIRE) — Teamwork and collaboration are essential to providing high-quality care. While research has found discrepancies between nurses’ and physicians’ perceptions in operating rooms, ICUs and labor and delivery units, less is known about perceptions on general medical services.

A new study, “A Multisite Study of Interprofessional Teamwork and Collaboration on General Medical Services,” in the December issue of The Joint Commission Journal on Quality and Patient Safety, assessed teamwork climate among nurses, nurse assistants and physicians/hospitalists working on general medical services in four mid-sized hospitals. Using the Safety Attitudes Questionnaire, respondents were asked to rate the quality of collaboration experienced with their own and other professional categories.

Among the 380 participants, median teamwork climate scores were significantly different across the four sites. In addition, ratings of the quality of collaboration differed significantly based on professional category. Specifically, 63.3% of hospitalists rated the quality of collaboration with nurses as high or very high, while 48.7% of nurses rated the quality of collaboration with hospitalists as high or very high.

Given the importance of teamwork in high-quality care and considering the variation across sites in the study, the researchers suggest that health care leaders consider conducting similar assessments to characterize teamwork and collaboration on general medical services within their own hospitals.

An accompanying editorial, “Measuring Collaboration in Health Care: Insights from the Science of Teamwork,” highlights three insights to guide future research on teamwork and collaboration in health care. “Although research on teamwork in health care provides some insights to explain differences in perceptions of collaboration by professional group, the current study leaves room for future research on interprofessional collaboration in health care,” notes the editorial.

Also featured in the December issue: 

For more information, visit The Joint Commission Journal on Quality and Patient Safety website.     

Note for
 
editors   
The article is “A Multisite Study of Interprofessional Teamwork and Collaboration on General Medical Services,” by Kevin J. O’Leary, MD, MS; Milisa Manojlovich, PhD, RN; Julie K. Johnson, MSPH, PhD; Ronald Estrella, MHA, RN; Krystal Hanrahan, MS, MSPH, RN; Luci K. Leykum, MD, MBA, MSc; G. Randy Smith, MD, MS; Jenna D. Goldstein, MA; and Mark V. Williams, MD. The article appears in The Joint Commission Journal on Quality and Patient Safety, volume 46, number 12 (December 2020), published by Elsevier.   


The Joint Commission Journal on Quality and Patient Safety
   
The Joint Commission Journal on Quality and Patient Safety (JQPS) is a peer-reviewed journal providing health care professionals with innovative thinking, strategies and practices in improving quality and safety in health care. JQPS is the official journal of The Joint Commission and Joint Commission Resources, Inc. Original case studies, program or project reports, reports of new methodologies or the new application of methodologies, research studies, and commentaries on issues and practices are all considered.   

Media Contact:   
Katie Bronk   
Corporate Communications    
(630) 792-5175   
[email protected]   
   
View the multimedia news release



Posted on

T-Mobile and UScellular Team Up to Further Protect Customers from Scams and Spam

T-Mobile and UScellular Team Up to Further Protect Customers from Scams and Spam

  • What’s the news: T-Mobile and UScellular deliver cross-network robocall protection with STIR/SHAKEN number verification. Now, calls between the two networks are authenticated to help fight number spoofing and further protect people from fraudsters.
  • Why it matters: Scams are the #1 complaint to the FCC. Today, scammers are preying on consumers’ growing financial and health fears during the coronavirus pandemic. Wireless companies must work together to verify calls across networks, so consumers know calls haven’t been spoofed.
  • Who it’s for: T-Mobile and UScellular customers who want the industry’s best scam and robocall protections, period.

BELLEVUE, Wash. & CHICAGO–(BUSINESS WIRE)–
Scammers get dealt another blow. T-Mobile (NASDAQ: TMUS) and UScellular (NYSE: USM) today announced they’re delivering STIR/SHAKEN number verification across networks marking another milestone in the industry’s ongoing fight to protect consumers from scams and unwanted robocalls. Now, when a call comes in from T-Mobile to UScellular’s network (or vice versa), the companies will be able to validate it’s coming from the real phone number displayed in Caller ID, providing customers better ability to make decisions on which calls to answer. Customers using T-Mobile, Metro by T-Mobile or UScellular have greater peace of mind that calls are not being spoofed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119006099/en/

(Photo: Business Wire)

(Photo: Business Wire)

“Scammers and spammers are constantly evolving. This summer we launched our Un-carrier move, Scam Shield, and we’re not letting up in our fight to stop scammers,” said Abdul Saad, Executive Vice President and Chief Technology Officer at T-Mobile. “We already have more cross-network STIR/SHAKEN partnerships than AT&T and Verizon combined. And Scam Shield, free to our customers, is the industry’s most comprehensive solution for fighting scams and robocalls. But this battle takes industry-wide action, and we stand ready to work with everyone to help them adopt STIR/SHAKEN and help keep consumers safe from scammers at this critical time.”

“At UScellular, we have our customers’ backs and are committed to helping them avoid unwanted and deceptive robocalls. Teaming up with T-Mobile allows us to provide our customers stronger protection in the ongoing fight against these unsolicited calls,” said Michael S. Irizarry, Ph.D., Executive Vice President and Chief Technology Officer, Engineering and Information Services at UScellular. “When wireless providers come together like this, it is a win for consumers and businesses, and we will continue to enhance the tools and solutions we offer to keep our customers safeguarded from scams.”

In summer 2020, T-Mobile launched another Un-carrier move: Scam Shield, an unparalleled set of free solutions to protect customers against scams and unwanted robocalls. With Scam Shield, T-Mobile and Metro by T-Mobile customers get automatic and free scam call detection as well as the option for free Caller ID and scam call blocking. According to research this summer from analysts at Global Data, T-Mobile’s network is already 30% better than AT&T and Verizon at identifying scam calls.

T-Mobile leads the industry in implementing the FCC STIR/SHAKEN standards, with eleven cross-network partnerships for number verification. T-Mobile was first to announce readiness for the FCC-recommended STIR/SHAKEN standards in November 2018 and first in the wireless industry to implement STIR/SHAKEN when it launched Number Verified (formally Caller Verified) on the Samsung Galaxy Note9 in January 2019.

And now, T-Mobile offers consumers more than 190 devices that can display either “Number Verified” or “T-Mobile Verified” in Caller ID or, depending on the device, a check mark in the call log. This works on any call coming from a compatible mobile phone at T-Mobile, Metro by T-Mobile or another company that has implemented STIR/SHAKEN with T-Mobile to verify the source of the call.

UScellular has taken additional actions to help solve the frustrating and costly issue of unwanted calls. Through the company’s network blocking solution, highly fraudulent robocalls are blocked before ever reaching customers on UScellular’s VoLTE network, significantly reducing the amount of unwanted calls they receive.

For an extra level of security, UScellular provides free and premium versions of the Call Guardian app for Android and iOS. The free app provides potential spam call identification based on known offenders and allows users to create a personal spam list. The premium version ($3.99 per month) provides added protection and features such as enhanced details for all potentially risky calls, the ability to block individual calls or block all calls for selected risk levels and Caller ID.

The FCC requires STIR/SHAKEN standards be implemented by June 30, 2021 to digitally ensure that a call is in fact from the number displayed on Caller ID. The acronym stands for Secure Telephone Identity Revisited (STIR) and Signature-based Handling of Asserted Information Using toKENs (SHAKEN). More calls will be verified over time as more device providers display number verification and as more network providers implement the standards.

For more information on all the ways T-Mobile is protecting customers, including capable handsets, visit https://www.t-mobile.com/resources/call-protection. For more information on how to avoid phone scams and keep yourself and loved ones safe during COVID-19, check out this Q&A with security expert Carrie Kerskie in the T-Mobile Newsroom.

For Metro by T-Mobile customers, more information is available, including capable handsets at https://www.metrobyt-mobile.com/scam-shield.

For more information on how UScellular is protecting customers from unwanted robocalls, please go to https://www.uscellular.com/support/robocall.

About T-Mobile

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.

About UScellular

UScellular is the fourth-largest full-service wireless carrier in the United States, providing national network coverage and industry-leading innovations designed to elevate the customer experience. The Chicago-based carrier is building a stronger network with the latest 5G technology and offers a wide range of communication services that enhance consumers’ lives, increase the competitiveness of local businesses and improve the efficiency of government operations. It is ranked #1 in the North Central Region in the J.D. Power 2020 Wireless Network Quality Performance Study – Volume 2. To learn more about UScellular, visit one of its retail stores or www.uscellular.com. To get the latest news, promos and videos, connect with UScellular on Facebook.com/uscellular, Twitter.com/uscellular and YouTube.com/uscellularcorp.

Media Contacts

T-Mobile US, Inc. Media Relations

[email protected]

UScellular

Katie Frey, Communications Manager

[email protected]

Investor Relations Contact

T-Mobile US, Inc.

[email protected]

http://investor.t-mobile.com

KEYWORDS: Illinois Washington United States North America

INDUSTRY KEYWORDS: Networks Security Mobile/Wireless Technology Telecommunications

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)
Posted on

Colgate Laboratory Tests Show Toothpaste and Mouthwash Neutralize 99.9% of the Virus That Causes COVID-19

Colgate Laboratory Tests Show Toothpaste and Mouthwash Neutralize 99.9% of the Virus That Causes COVID-19

Clinical Research Program Underway To Validate Potential of Oral Health Products to Slow Spread of the Virus

NEW YORK–(BUSINESS WIRE)–
Laboratory studies show that toothpastes containing zinc or stannous and mouthwash formulas with cetylpyridinium chloride (CPC) neutralize the virus that causes COVID-19 by 99.9 percent. The studies are part of a Colgate research program that includes clinical studies among infected people to assess the efficacy of oral care products in reducing the amount of the virus in the mouth, potentially slowing the transmission of the COVID-19 virus.

In the laboratory studies — the first to include toothpaste — Colgate Total and Meridol toothpastes neutralized 99.9% of the virus after two minutes of contact. Colgate Plax and Colgate Total mouthwashes were similarly effective after 30 seconds. The studies, completed in October, were conducted in partnership with Rutgers New Jersey Medical School’s (NJMS) Public Health Research Institute and Regional Biosafety Laboratories.

The results suggest that some toothpastes and mouthwashes may help reduce the spread of SARS-CoV-2, the virus that causes COVID-19, by temporarily reducing the amount of virus in the mouth. The virus spreads through respiratory droplets or small particles produced when an infected person coughs, sneezes, sings, talks, or breathes, according to the U.S. Centers for Disease Control and Prevention.

“We’re at the early stages of our clinical investigations, but our preliminary laboratory and clinical results are very promising,” said Dr. Maria Ryan, Colgate’s Chief Clinical Officer. “While brushing and rinsing are not a treatment or a way to fully protect an individual from infection, they may help to reduce transmission and slow the spread of the virus, supplementing the benefit we get from wearing masks, social distancing and frequent hand washing.”

Said Dr. David Alland, Chief of Infectious Diseases and Director of the Center for COVID-19 Response and Pandemic Preparedness, who led the Rutgers NJMS study along with colleagues Drs. Pradeep Kumar and Riccardo Russo: “Given that saliva can contain amounts of virus that are comparable to that found in the nose and throat, it seems likely that SARS-CoV-2 virus originating in the mouth contributes to disease transmission, especially in persons with asymptomatic COVID-19, who are not coughing. This suggests that reducing virus in the mouth could help prevent transmission during the time that oral care products are active.”

Concurrent to the laboratory study, Colgate sponsored a clinical study involving some 50 hospitalized subjects with COVID-19. This study demonstrated the ability of Colgate Total (with CPC and zinc), Colgate Peroxyl, and Colgate PerioGard mouthwashes to substantially reduce the amount of the virus in the mouth temporarily. The researchers plan to share their findings in December. Additional Colgate-supported clinical research studies on toothpaste and mouthwashes are in early stages at Rutgers, the Albert Einstein Institute in Sao Paulo, Brazil, and at the University of North Carolina at Chapel Hill Adams School of Dentistry, with some 260 people with COVID-19 participating in these studies.

“Colgate is collaborating with numerous investigators throughout the globe to conduct clinical research to explore the potential of oral care products to reduce oral viral loads as a risk reduction strategy,” Dr. Ryan said. “We think oral care has a role to play in fighting the global pandemic, alongside other preventive measures.”

Said Dr. Mark Wolff, Morton Amsterdam Dean of Penn Dental Medicine at the University of Pennsylvania: “With this pandemic, the more we understand about the virus, the more effective we can be in fighting it, so I am excited to see the impressive research program Colgate has undertaken. We need to continue to take the precautions recommended by health authorities, and with these studies we may demonstrate an additional way to address the transmission of disease among people in close contact, particularly in dental practice. That would be an important advance.”

As the world’s #1 trusted dental expert, Colgate is committed to leading in science and to ensuring that its products address health challenges and meet consumers’ needs. For more information about the effects of oral hygiene on overall health and additional insights on mask mouth and other topics, visit www.colgate.com.

About Colgate-Palmolive:

Colgate-Palmolive Company is a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. Focused on Oral Care, Personal Care, Home Care and Pet Nutrition and reaching more than 200 countries and territories, Colgate teams are developing and selling health and hygiene products and pet nutrition offerings essential to society through brands such as Colgate, Palmolive, elmex, meridol, Tom’s of Maine, hello, Sorriso, Speed Stick, Softsoap, Irish Spring, Protex, Sanex, Filorga, eltaMD, PCA Skin, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. Colgate seeks to deliver sustainable, profitable growth and superior shareholder returns and to provide Colgate people with an innovative and inclusive work environment. Colgate does this by developing and selling products globally that make people’s lives healthier and more enjoyable and by embracing its sustainability, diversity, equity and inclusion and social responsibility strategies across the organization. For more information about Colgate’s global business, its efforts to improve the oral health of children through its Bright Smiles, Bright Futures program and how the Company is building a future to smile about, visit www.colgatepalmolive.com. CL-C

Thomas DiPiazza

Colgate-Palmolive Company

212-310-2607

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Health Dental Other Science General Health Research Science

MEDIA:

Logo
Logo
Posted on

SOC Telemed to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire

RESTON, VA
 , Nov. 19, 2020 /PRNewswire/ — SOC Telemed, Inc. (Nasdaq:  TLMD), one of the largest national providers of acute care telemedicine, today announced that John Kalix, Chief Executive Officer, and Hai Tran, Chief Operating Officer and Chief Financial Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020. A link to the audio recording will be available at https://investors.soctelemed.com/.

About SOC Telemed

SOC Telemed (SOC) is the largest national provider of telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC’s technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry and teleICU, enabling healthcare organizations to build sustainable telemedicine programs in any clinical specialty. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission’s Gold Seal of Approval and has maintained that accreditation every year since inception. For more information, visit www.soctelemed.com.

Media Relations:

Lauren Shankman

Trevelino/Keller
[email protected]

Investor Relations:
Bob East or Jordan Kohnstam
Westwicke, an ICR company
[email protected]
(443) 213-0500

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/soc-telemed-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare-conference-301177483.html

SOURCE SOC Telemed

Posted on

F-35 Proposal Submitted to Swiss Government

The 5th Generation F-35 provides unmatched capabilities, autonomy and industrial opportunities for Switzerland

PR Newswire

FORT WORTH, Texas, Nov. 19, 2020 /PRNewswire/ — On Nov. 18, the U.S. government and Lockheed Martin (NYSE: LMT) submitted an F-35 proposal to the Swiss government in support of Switzerland’s New Fighter Aircraft (NFA) competition.

The F-35 proposal is a total package offering that includes up to 40 F-35A aircraft, a sustainment solution tailored to Swiss autonomy requirements, and a comprehensive training program.

The offering includes an industrial package providing Swiss industry substantial F-35 work opportunities. Should the F-35 be selected as the new fighter for Switzerland, this industrial work would take place in all Swiss regions. Swiss industry has the opportunity to compete for direct production of components for use on all F-35s produced, sustainment projects focused on supporting the Swiss Air Force and enhancing Swiss autonomy, and cyber security projects directly related to the F-35.

The offer uses the F-35 Global Support Solution for sustainment to ensure Switzerland benefits from the European F-35 economies of scale to realize lower sustainment costs for the Swiss Air Force. It also includes a six-month spares package to ensure the Swiss Air Force has the ability to conduct autonomous operations, if needed. Lockheed Martin is also offering an option for the assembly of four aircraft in Switzerland to ensure the Swiss Air Force and Swiss industry gain an understanding of how to maintain the F-35 airframe and its advanced capabilities for the life of the program.

“We are confident that our F-35 offer is the best and most affordable solution for the Swiss NFA competition,” said Greg Ulmer, F-35 Program vice president and general manager. “We are offering the only 5th generation fighter at the cost of 4th generation aircraft while offering Switzerland an aircraft that will protect Swiss sovereignty for decades to come.”

To date, the F-35 has been selected by 13 nations and operates from 26 bases worldwide, with nine nations operating F-35s on their home soil. There are more than 585 F-35s in service today, with more than 1,190 pilots and 9,750 maintainers trained on the aircraft. 

For additional information, visit www.f35.com.

About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 110,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services. For additional information, visit our website: www.lockheedmartin.com.

Please follow @LMNews on Twitter for the latest announcements and news across the corporation.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/f-35-proposal-submitted-to-swiss-government-301177478.html

SOURCE Lockheed Martin Aeronautics

Posted on

American Public University System Renames its School of Business in Honor of President Emeritus Dr. Wallace E. Boston

Naming Pays Tribute to Dr. Boston Building APUS as a Trailblazer of Affordable Online Higher Education

PR Newswire

CHARLES TOWN, W.Va., Nov. 19, 2020 /PRNewswire/ — American Public University System (APUS) has renamed its business school the Dr. Wallace E. Boston School of Business, to commemorate Dr. Boston’s nearly two decades of leadership as a C-level executive and board member at APUS and its parent company, American Public Education, Inc. (Nasdaq: APEI). 

Dr. Boston led APUS as President and CEO during a period of accelerated growth – in both student enrollment and revenue. APUS has 86,300 active students (as of Sept. 30, 2020), roughly ten times the size of the student body at the start of his 15-year tenure. Dr. Boston, now president emeritus at APUS, previously served as APUS president up until his retirement in August 2020 and had also served as CEO of APEI through September 2019.  

“Dr. Boston has an unwavering commitment to student success and has not only built our university into a premier online higher education provider, he has helped define the future of online education,” said APUS Board of Trustees Chairman Alfred M. Gray, the 29th Commandant of the U.S. Marine Corps. “Our School of Business is building on this strong foundation, and it provides a relevant, accessible and inclusive learning environment for tomorrow’s aspiring business leaders.”

APUS’s School of Business has conferred more than 26,500 degrees and certificates. The School offers 51 online degree and certificate programs; 22 degrees are at the master’s and bachelor’s levels, including the Master of Business Administration (MBA) and Bachelor of Business Administration (BBA).

“I’m deeply honored by the tribute and am confident that the school will help students achieve rewarding careers for generations to come,” said Dr. Boston. “I have been fortunate to work with so many dedicated individuals to help better prepare hundreds of thousands of students for successful careers across private sector, public service and the military.”

Dr. Boston helped APUS and APEI achieve many milestones including a successful initial accreditation with the Higher Learning Commission of the North Central Association in 2006, the initial public offering on NASDAQ in 2007, and the acquisition of the Hondros College of Nursing (in 2013). His dedication to making higher education affordable and accessible has resulted in APUS being well positioned for the future.

The APUS School of Business’s mission is to prepare students to be principled leaders in the global business community by leveraging technology and best practices focused on the practical application of knowledge. The school’s courses are reviewed on an ongoing basis in consultation with industry leaders from Fortune 500 companies and beyond. APUS’s undergraduate and graduate business programs have specialty accreditation from the Accreditation Council for Business Schools and Programs (ACBSP), an affiliation achieved in 2011. The BA in Human Resources and the BA in Management, Human Resource Concentration have been approved by the Society for Human Resource Management (SHRM) for being in alignment with its educational standards.

The Business School offers numerous associate, bachelor’s, and master’s degree programs and certificate courses including business, management, transportation and logistics, entrepreneurship, analytics and supply chain management. All programs address core topics such as accounting, management, operations, human resources, international business, and economics, to prepare our graduates transitioning in the global world of work.

Supporting Resources

About American Public University System
American Public University System, recipient of the Online Learning Consortium’s (OLC) Gomory Award for Quality Online Education and five-time recipient of OLC’s Effective Practice Award, offers more than 200 online degree and certificate programs through American Public University and American Military University, the #1 provider of education to the U.S. military* and the top university nationwide for veterans using their GI Bill benefit** (based on student enrollment data). Over 101,400 alumni worldwide have benefited from APUS’s inclusive, relevant curriculum and flexible online delivery model. For more information, visit www.apus.edu.
*Based on FY 2019 DoD tuition assistance data, as reported by Military Times, 2020.
**Based on FY 2019 Department of Veterans Affairs (VA) data, as reported by Military Times, 2020.  

CONTACT

Frank Tutalo

Director of Public Relations
571-358-3042
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/american-public-university-system-renames-its-school-of-business-in-honor-of-president-emeritus-dr-wallace-e-boston-301177460.html

SOURCE American Public University System

Posted on

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Wells Fargo & Company (WFC)

Shareholders with $50,000 losses or more are encouraged to contact the firm

PR Newswire

LOS ANGELES, Nov. 19, 2020 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 29, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Wells Fargo & Company (“Wells Fargo” or the “Company”) (NYSE: WFC) common stock between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Wells Fargo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/wells-fargo-and-company/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On April 14, 2020, Wells Fargo announced its first quarter 2020 financial results in a press release. Therein, the Company announced a $4 billion provision expense to account for expected credit delinquencies, including $940 million in net charge-offs on loans and debt securities and a $3.1 billion reserve build.

On this news, the Company’s stock price fell $4.54, or 14%, over three consecutive trading sessions to close at $26.89 per share on April 16, 2020.

On May 5, 2020, Wells Fargo filed its quarterly report with the SEC for first quarter 2020, in which it stated that Wells Fargo’s collateralized loan obligations (“CLOs”) investments fell 9% and that the Company suffered $1.7 billion in unrealized losses on its CLO investments during the quarter.

On this news, the Company’s stock price fell $1.74, or 6%, over two consecutive trading sessions to close at $25.61 per share on May 6, 2020.

On June 10, 2020, Wells Fargo’s Chief Financial Officer, John Shrewsberry, presented at the Morgan Stanley Virtual US Financials Conference, during which he stated that the second quarter reserve build would be even “bigger than the first quarter” due to continued deterioration in the Company’s credit portfolio.

On this news, the Company’s stock price fell $5.84, or 18%, over two consecutive trading sessions to close at $26.79 per share on June 11, 2020.

On July 14, 2020, Wells Fargo announced its second quarter 2020 financial results in a press release, disclosing a $9.5 billion provision expense to account for expected credit delinquencies.

On this news, the Company’s stock price fell $1.16, or 5%, to close at $24.25 per share on July 14, 2020.

On October 14, 2020, Wells Fargo announced a $769 million provision expense for third quarter 2020, but the Company’s CFO stated that further deterioration of the credit portfolio had been forestalled due to short-term customer accommodations provided since the start of the pandemic.

On this news, the Company’s stock price fell $1.49, or 6%, to close at $23.25 per share on October 14, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loans were to customers of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, CLOs and CMBS on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, the Company’s statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading; and (8) as a result of the foregoing, the Company was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased Wells Fargo common stock during the Class Period, you may move the Court no later than December 29, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-wells-fargo–company-wfc-301177477.html

SOURCE Glancy Prongay & Murray LLP

Posted on

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN)

PR Newswire

BENSALEM, Pa., Nov. 19, 2020 /PRNewswire/ —  ­­Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”).  

Investors suffering losses on their Neovasc investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

In December 2018, the Company filed a Q-Sub submission to the U.S. Food and Drug Administration (“FDA”) that contained safety and efficacy results from Neovasc’s clinical studies, as well as supporting data from peer-reviewed journals.

On February 20, 2019, Neovasc announced that, despite “Breakthrough Device Designation,” the FDA review team recommended that the Company collect further pre-market blinded data prior to submitting a Pre-Market Approval (“PMA”) application.

On November 1, 2019, the Company announced that it would submit a PMA application for the Reducer without gathering further evidence, against the FDA’s recommendation. Neovasc claimed that “the clinical evidence already available will be sufficient to not further delay the availability of this Breakthrough medical device for the treatment of U.S. patients.”

On October 28, 2020, before the market opened, the Company announced that an FDA advisory panel voted overwhelmingly against the safety and effectiveness of the Reducer. The panel noted concerns with the Company’s clinical data, including “that the lack of blinding assessment made the primary endpoint difficult to interpret.” As a result, the panel reached a consensus “that additional premarket randomized clinical data was necessary.”

On this news, the Company’s share price fell $0.77, or 42%, to close at $1.06 per share on October 28, 2020, on unusually heavy trading volume.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Neovasc securities during the Class Period, you may move the Court no later than January 5, 2021to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

Cision View original content:http://www.prnewswire.com/news-releases/deadline-reminder-law-offices-of-howard-g-smith-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-neovasc-inc-nvcn-301177455.html

SOURCE Law Offices of Howard G. Smith

Posted on

DEINOVE signs an Evaluation and Technology Development License with DSM

DEINOVE signs an Evaluation and Technology Development License with DSM

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment to tackle the global challenge of antimicrobial resistance and the need for next-generation active ingredients for Health, announces the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living.

Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.

“This collaboration with a major player in the field of animal nutrition is totally in line with our R&D partnering strategy in the non-therapeutic activities and underlines the quality of the work that has been done in the Color-2B program”
commented Alexis Rideau, Deputy CEO of DEINOVE.
“We hope that the evaluation and technology development program will lead to the launch of a new active ingredient that has been brought to light by DEINOVE from its proprietary strain collection.”

ABOUT DEINOVE

DEINOVE is a French biotech company pioneer in the exploration and exploitation of biodiversity from the natural environment to tackle the global challenge of antimicrobial resistance and the need for next-generation active ingredients for Health.

The Company has built a unique collection of over 10,000 bacterial strains and has developed a fully integrated technological platform that brings together the best of biological culture, synthetic biology and micro-biotechnology.

Today, DEINOVE has several development programs underway, including the antibiotic candidate   DNV3837, in a Phase II clinical trial in severe gastrointestinal infections with Clostridioides difficile, a real therapeutic challenge. Through its other program AGIR (Antibiotics against Resistant Infectious Germs), supported by Bpifrance, it is also continuing its exploration of biodiversity to supply its portfolio with new molecules. It relies on its own biodiversity and on the one entrusted to it by other specialists in the field.

DEINOVE has also developed and brought to market four particularly innovative active ingredients: two products produced by Deinococcus geothermalis (phytoene and neurosporene), as well as two cell extracts developed in collaboration.

DEINOVE, located in the Euromédecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally. It is listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056).

CONTACTS

Investors
Mario Alcaraz
Chief Financial and Administrative Officer
Phone: +33 (0)4 48 19 01 00
[email protected]

 

Media                                                                                                      
ALIZE RP – Caroline Carmagnol
Phone: +33 (0)6 64 18 99 59
[email protected]
 

 

Attachment